CEO Helen Torley Files to Sell $23.7M in Halozyme Stock
HALO sits 68% above its 52-week low of $61.225.
Summary
CEO Helen Torley plans to sell 240,000 shares (~$23.7M) under a 10b5-1 plan, adding to recent insider selling pressure.
Key Events · Ownership and Investor Activity · HALO
-
CEO Files to Sell $23.7M in Stock
Helen Torley, President, CEO, and Director, filed a Form 144 to sell 240,000 shares with an approximate market value of $23,678,400.
-
Sale Under Pre-Arranged 10b5-1 Plan
The sale is part of a 10b5-1 trading plan adopted on December 3, 2025, indicating the disposition was planned in advance.
-
Recent Insider Selling Pattern
This filing follows other insider sales, including a $4.3M sale by former COO Cortney Caudill on August 11, 2026, and a smaller sale by Director Bernadette Connaughton on August 10, 2026.
-
Stock Near 52-Week High
The proposed sale comes as Halozyme trades near its 52-week high of $104.78, potentially reflecting profit-taking after strong Q2 results.
Analysis · HALO · Life Sciences
CEO Helen Torley filed a Form 144 to sell 240,000 shares worth approximately $23.7 million, acquired via option exercise. This is a significant insider sale, especially given the stock is trading near its 52-week high of $104.78. The sale is part of a pre-arranged 10b5-1 plan adopted in December 2025, which reduces the signal of opportunistic selling but still represents a large liquidity event by the top executive.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HALO was trading at $103.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.7B. The 52-week trading range was $61.23 to $104.78. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.